SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026
SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29 to June 2 in Chicago.
Key poster presentations highlight the expanding body of evidence supporting Pathlight™, SAGA’s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings. Retrospective analysis of PADA-1 samples will explore ctDNA kinetics during first-line therapy in metastatic breast cancer, while the real-world CITCCA cohort will evaluate Pathlight in colon and rectal cancer, through assessment of ctDNA clearance, recurrence risk, and outcomes in localized disease.
“As MRD testing becomes increasingly important in oncology, clinicians need assays capable of detecting patient-specific molecular residual disease at the lowest possible levels across a broad range of clinical settings,” said Wendy Levin, MD, MS, Chief Clinical Officer at SAGA Diagnostics. “The data being presented at ASCO 2026 further highlight the potential of Pathlight’s ultrasensitive tumor-informed ctDNA approach to support treatment monitoring, recurrence assessment, and longitudinal disease surveillance across both metastatic and localized cancers.”
